Skip to main content
editorial
. 2021 Apr 15;9(6):2135–2138. doi: 10.1016/j.jaip.2021.03.053

Figure 1.

Figure 1

Prevaccine high risk patients and dose 1 vaccination outcome (n = 16). Among the 16 individuals skin tested after risk stratification, only 1 individual was skin test positive (oral PEG severe allergic reaction, tolerated Janssen vaccine). Thirteen of the 15 skin test negative individuals tolerated the initial dose of COVID-19 vaccine. ∗Two skin test negative individuals are awaiting dose 1 of the COVID-19 vaccine: 1 employee with a history of severe allergic reaction to vaccine or injectable containing PEG/polysorbate and 1 employee with a history of severe allergic reaction to vaccine or injectable. †One employee experienced pruritus on lower back immediately after Pfizer dose 1 was given 10 mg cetirizine with complete resolution of symptoms in 30 minutes. Tolerated Pfizer dose 2 without any allergic symptoms.